Healthcare's most forward-thinking voices come together in a new collaborative series recorded at AI Med 2025. Outcomes Rocket and Censinet today announced the AI Med 2025 Insights Series, a special podcast program recorded live at the AI Med 2025 Conference. Co-hosted by Saul Marquez, CEO of Outcomes Rocket, and Ed Gaudet, CEO of Censinet and […]

NEW YORK, NY / ACCESS Newswire / November 7, 2025 / Levi & Korsinsky, LLP releases a Podcast regarding WPP plc (NYSE:WPP) class action securities lawsuit A Class Action lawsuit was filed on behalf of WPP plc investors who lost money as a result of alleged securities fraud between February 27, 2025 and July 8,

NEW YORK, NY / ACCESS Newswire / November 7, 2025 / Levi & Korsinsky, LLP releases a Podcast regarding Baxter International, Inc. (NYSE:BAX) class action securities lawsuit A Class Action lawsuit was filed on behalf of Baxter International, Inc. investors who lost money as a result of alleged securities fraud between February 23, 2022 and

GOATT Golf Club successfully hosted its inaugural member event at Erin Hills Golf Course, home to the 2017 U.S. Open and one of America's Top 100 courses along with 18 holes at the Legend at Merril Hills on July 28-29, 2025. Bringing together members and players from 13 clubs within its network for two unforgettable

(NasdaqGM:ALT), AI-based digital pathology analysis provides high-resolution quantification of hepatic fibrosis and objective measurement of fibrosis improvement Pemvidutide demonstrated significant reductions in liver fibrosis and improvements in non-invasive tests vs. placebo at 24 weeks GAITHERSBURG, Md., Nov. 07, 2025 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics

(NASDAQ:IMNN), Investors and stakeholders invited to attend in person in New York City or via live webcast on Monday, November 10th at 8:00 a.m. ET LAWRENCEVILLE, N.J., Nov. 07, 2025 (GLOBE NEWSWIRE) — IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, will host an R&D Day on Monday,

(NASDAQ:TMCI), PONTE VEDRA, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) — Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced it will participate in the following upcoming investor conferences. The UBS Global Healthcare Conference on

International Tower Hill Mines Ltd. (the “Company”) – (TSX: ITH) (NYSE American: THM) today announced that it has filed its unaudited third quarter Financial Statements and associated Management Discussion and Analysis and Quarterly Report on Form 10-Q for the three- and nine-month period ended September 30, 2025. Shareholders can obtain copies of the Company's unaudited

Treace Announces Participation in Two Upcoming Investor Conferences GlobeNewswire November 07, 2025 PONTE VEDRA, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) — Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced it will participate in

Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting(R) 2025 GlobeNewswire November 07, 2025 AI-based digital pathology analysis provides high-resolution quantification of hepatic fibrosis and objective measurement of fibrosis improvement Pemvidutide demonstrated significant reductions in liver fibrosis and improvements